(Q38991433)

English

Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy

scientific article

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Methotrexate inhibits the viability of human melanoma cell lines and enhances Fas/Fas-ligand expression, apoptosis and response to interferon-alpha: rationale for its use in combination therapy (English)

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

1 reference

based on heuristic

inferred from title

author name string

Minakshi Nihal

1

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Jianqiang Wu

2

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Gary S Wood

3

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

language of work or name

0 references

publication date

23 May 2014

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

number of pages

7

1 reference

based on heuristic

inferred from page(s)

Archives of Biochemistry and Biophysics

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

563

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

101-107

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Combination therapies for the treatment of advanced melanoma: a review of current evidence.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Combinations of radiation therapy and immunotherapy for melanoma: a review of clinical outcomes

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Dabrafenib for treatment of BRAF-mutant melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Treatment of BRAF-mutant melanoma: the role of vemurafenib and other therapies

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Complete response to multidisciplinary therapy in a patient with primary gastric choriocarcinoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Directed phenotype switching as an effective antimelanoma strategy.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Which drug, and when, for patients with BRAF-mutant melanoma?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Systematic review and meta-analysis of randomized trials of central nervous system directed therapy for childhood acute lymphoblastic leukemia

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

The impact of folate status on the efficacy of colorectal cancer treatment.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Methotrexate used in combination with aminolaevulinic acid for photodynamic killing of prostate cancer cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Methotrexate and Ras methylation: a new trick for an old drug?

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Doxorubicin in combination with fluorouracil and cyclophosphamide (i.v. FAC regimen, day 1, 21) versus methotrexate in combination with fluorouracil and cyclophosphamide (i.v. CMF regimen, day 1, 21) as adjuvant chemotherapy for operable breast canc

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Death receptors and melanoma resistance to apoptosis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Recent advances in the management of squamous cell carcinoma of the head and neck

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Drug-resistance in human melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Fas and Fas ligand interactions suppress melanoma lung metastasis

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

The Fas counterattack: Fas-mediated T cell killing by colon cancer cells expressing Fas ligand

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Pattern of chromosomal replication in synchronized lymphocytes. I. Evaluation and application of methotrexate block

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Melanoma coordinates general and cell-specific mechanisms to promote methotrexate resistance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Activation-dependent transcriptional regulation of the human Fas promoter requires NF-kappaB p50-p65 recruitment

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

9 September 2017

Reduction of Fas/CD95 promoter methylation, upregulation of Fas protein, and enhancement of sensitivity to apoptosis in cutaneous T-cell lymphoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

14 September 2017

Mechanism of dihydrofolate reductase downregulation in melanoma by 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

14 September 2017

Combination chemotherapy for advanced adenocarcinoma of the lung. A review

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

14 September 2017

Combination Chemotherapy with Vinblastine, Bleomycin and Methotrexate in Dtic-resistant Metastatic Melanoma

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

14 September 2017

The critical role of alpha-folate receptor in the resistance of melanoma to methotrexate.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

14 September 2017

Low FAS/CD95 expression by CTCL correlates with reduced sensitivity to apoptosis that can be restored by FAS upregulation

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

14 September 2017

Targeting the methionine cycle for melanoma therapy with 3-O-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

14 September 2017

Gene amplification in cultured animal cells

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

14 September 2017

Differential increase of Fas ligand expression on metastatic and thin or thick primary melanoma cells compared with interleukin-10.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

25 September 2017

Multidrug resistance: molecular biology and clinical relevance.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

17 June 2018

Melanoma activation of 3-o-(3,4,5-trimethoxybenzoyl)-(-)-epicatechin to a potent irreversible inhibitor of dihydrofolate reductase.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

21 August 2018

Frequent downregulation of Fas (CD95) expression and function in melanoma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

21 August 2018

Heterogenous susceptibility to CD95-induced apoptosis in melanoma cells correlates with bcl-2 and bcl-x expression and is sensitive to modulation by interferon-gamma.

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4319533

21 August 2018

Involvement of the CD95 (APO–1/Fas) receptor/ligand system in drug–induced apoptosis in leukemia cells

1 reference

https://pubmed.ncbi.nlm.nih.gov/24862567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Interferon and low dose methotrexate improve outcome in refractory mycosis fungoides/Sézary syndrome

1 reference

https://pubmed.ncbi.nlm.nih.gov/24862567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Melanoma cell expression of Fas(Apo-1/CD95) ligand: implications for tumor immune escape

1 reference

https://pubmed.ncbi.nlm.nih.gov/24862567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Increased soluble CD95 (sFas/CD95) serum level correlates with poor prognosis in melanoma patients

1 reference

https://pubmed.ncbi.nlm.nih.gov/24862567

12 December 2020

based on heuristic

inferred from PubMed ID database lookup

Identifiers

10.1016/J.ABB.2014.04.019

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

PMC publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

PubMed publication ID

1 reference

Europe PubMed Central

PMC publication ID

8 September 2017

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38991433&oldid=1801099134"